Purpose: The purpose of this study was to assess the effect that changes in sex hormone levels have on intraocular pressure (IOP) in menopausal women.
A number of studies provide clinical evidence that aging is associated with increases in intraocular pressure (IOP). [1] [2] [3] [4] IOP does not change significantly until the fourth decade and then increases in both sexes. 4 The impact of aging, however, varies according to gender. Male-female differences in IOP are small until the 40 to 49 years age group, after which women begin to develop significantly higher IOPs than men. 1, 4 IOP differences between the two sexes might be attributed to hormonal differences between them. Many studies have indicated an association between IOP and hormonal status in women. Mean IOP in postmenopausal women has been reported to be higher than that in menstruating women in the same age group. [3] [4] [5] [6] Decreased IOP has been reported during late pregnancy, 4, 5, [7] [8] [9] [10] possibly due to an improved facility of aqueous outflow. 7, 8 Moreover, although controversy exists, 4, 5, 11 there are data suggesting that IOP and coefficient of outflow changes at various points in the menstrual cycle. 7, 8 Altogether, these data point out the possible influence of sex hormones on IOP. Pharmacological doses of progesterone and estrogen (alone or in combination) can influence IOP. Paterson and Miller 8 reported that 50 mg progesterone injected intramuscularly into various subjects caused a fall in IOP. Similarly, estrogen or combined estrogen progestin treatment has been shown to induce reduction in IOP both in normal eyes 12, 13 and in eyes with glaucoma. 14, 15 Contrary to these findings, a recent study suggested that elevated progesterone levels were associated with higher IOPs in lions. 16 Similarly, topical administration of progesterone has been reported to increase IOP in rabbit eyes. 17 Ziai et al 10 reported that changes in IOP observed during pregnancy were associated with serum levels of progesterone. However, attempts to correlate endogenous levels of sex hormones (estrogen, progesterone, testosterone, FSH, and LH) during phases of the menstrual cycle and aqueous hemodynamics failed to demonstrate any significant associations. [18] [19] [20] The relationship between hormonal changes associated with menopause and IOP has not been studied previously. Therefore, our objective in this study was to examine the possible relationship between the physiological levels of sex hormones (estradiol, free testosterone, and FSH) and IOP in menopausal women.
SUBJECTS AND METHODS
A total of 54 white women with natural menopause were enrolled in the study. An informed consent was obtained from each subject after the nature of the study was explained. The design of the study was approved by the Ethical Committee of our institute. Subjects were chosen from those attending postmenopausal outpatient clinics at the Marmara University Hospital. A detailed medical and ophthalmic history was recorded and all of the subjects completed an ophthalmologic examination. The criteria met by the subjects were absence of any history of eye disease or surgery, absence of diabetes mellitus (fasting blood glucose < 110 mg/dl), uncontrolled hypertension (blood pressure > 160/100 mm Hg), smoking, hypercholesterolemia (total cholesterol > 200 mg/dl), cardiovascular, or peripheral vascular disease. The first group included 32 postmenopausal women between the ages of 45 and 65 (mean 52.1 ± 4.1). Postmenopausal status was defined as more than 1 year amenorrhea and FSH greater than 20 IU/ml. No subject had received any exogenous sex steroid since the time of menopause. The second group included 30 postmenopausal women between the ages of 47 to 64 years (mean 52.7 ± 4.5), who had been receiving combined hormone replacement therapy (0.625 mg conjugated estrogen with 2.5 mg medroxyprogesterone acetate) with a mean duration of 4 years (range, 1 to 12 years).
All patients were examined between 1000 and 1100 hours. Intraocular pressures were measured with Goldmann applanation tonometer. Three consecutive readings of each eye were taken and the average of these measurements was recorded for each eye.
Simultaneous blood samples (10 mL) were collected for the assessment of serum sex hormone levels. The blood samples were centrifuged and the resulting serum was stored at −20°C until assay. Serum estradiol levels were evaluated using chemiluminescent immunoassay by Immulite analyzer (Diagnostic Products Corp., Los Angeles, CA). Serum free-testosterone levels were determined with the radioimmunoassay by Count-A-Count analyzer (Diagnostic Products Corp., Los Angeles, CA). Serum FSH levels were measured by the electrochemiluminescent immunoassay by Elecsys 1010/2010 Modular analytics E170 analyzer (Roche Diagnostics GmbH, Mannheim, Germany).
Statistical Analysis
For statistical analysis, SPSS/PC 11.5 (SPSS Inc., Chicago, IL) was used. No statistical difference was found between IOP measurements of fellow eyes by unpaired t test (P ‫ס‬ 0.40), so the mean value for right and left eye of each subject was used for further statistical comparisons. The differences between two study groups in age, duration of amenorrhea, serum sex hormone levels, and IOPs were determined by means of unpaired t test. Associations between IOP and serum levels of estradiol, testosterone, and FSH were analyzed by Spearman's correlation test. (P < 0.05 was considered statistically significant.)
RESULTS
The subject characteristics and the mean values for serum sex hormone levels are shown in Table 1 . Two groups did not significantly differ in age and duration of amenorrhea. Serum estradiol level of menopausal women receiving HRT was significantly greater than that of menopausal women not receiving HRT (P < 0.0001). Serum testosterone levels were found to be significantly lower in menopausal women on HRT (P ‫ס‬ 0.001). Serum FSH levels did not differ between the two groups (P ‫ס‬ 0.49).
The mean IOP of menopausal women receiving HRT (13.29 ± 2.28 mm Hg) was not significantly different from that of menopausal women not receiving HRT (13.56 ± 2.5 mm Hg, P ‫ס‬ 0.24).
To examine the possible correlation between the hormonal milieu of menopause and IOP, the correlation between each of the three hormones (estradiol, free testosterone, and FSH) and IOP was studied (Table 2) . When we analyzed subjects by HRT status, IOP positively correlated with increases in testosterone levels in both groups (receiving HRT; r ‫,84.0ס‬ P ‫ס‬ 0.02 and not receiving HRT; r ‫,24.0ס‬ P ‫ס‬ 0.003). No significant correlations could be found between IOP and serum levels of estradiol or FSH.
DISCUSSION
The influence of hormonal status on IOP and aqueous outflow has been debated over several years. In 1921, the relationship between IOP and gonadal function was first reported by Imre 21 , who thought that increased concentrations of estrogen were associated with glaucoma. In the subsequent studies, the effects of menstrual cycle, pregnancy, menopause, and HRT on IOP were investigated. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [18] [19] [20] Paterson and Miller 8 demonstrated some alterations in IOP and coefficient of outflow at various phases in the menstrual cycle. They found that the rate of aqueous outflow rose to a peak at two phases of the menstrual cycle: the mid-follicular phase, which coincides with a rise in estrogen, and the luteal phase, which coincides with a rise in both estrogen and progesterone. Their results are in contradiction with the findings of an earlier study by Becker and Friedenwald 7 , who reported an increased facility of outflow during the progestational phase and a decreased facility during the estrogenic phase of the menstrual cycle. However, a number of recent studies have failed to find any relationship between days of the menstrual cycle or circulating hormone levels and variations in IOP. [18] [19] [20] Pregnancy, a time of significant increase in circulating estrogen and progesterone, has been associated with a decrease in IOP and an increase in aqueous outflow facility. 4 ,5,7-10 Progesterone 7,8,10 and relaxin 8 hormones have been suggested as the likely effectors of these alterations in IOP and outflow facility. Estrogen and progesterone production by the ovaries does not continue beyond menopause and circulating levels of these hormones fall considerably after menopause. Existing literature shows that IOP increases in the postmenopausal period. [4] [5] [6] Moreover, it has been reported that combined estrogen-progesterone therapy in menopausal patients induces statistically significant drop in IOP, 4 to 6 weeks after the initiation of therapy, in both normal and glaucomatous eyes. [13] [14] [15] These findings were confirmed by Treister and Mannor
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, who also showed that pure estrogen replacement therapy lowers IOP in non-glaucomatous eyes on average to the same extent as the combination therapy and that the pressure decrease is mainly associated with an increase in the outflow facility. Our findings, as obtained in this cross-sectional study, could not demonstrate a favorable effect of HRT on IOP. Although the mean IOP of postmenopausal women receiving HRT was lower compared with those not having received HRT, this difference was not of statistical significance.
In the present study, the correlation analysis revealed significant positive correlations between serum levels of free testosterone and IOP, which has not been previously documented. However, we were unable to establish any influence of estradiol or FSH levels on IOP. A possible limitation of the present study may be that the IOP and serum sex hormone level measurements were performed only once between 10:00 and 11:00 o'clock. Performing serial measurements of IOP and serum level of sex hormones during the day would better define the role that these hormones may play in the regulation of the diurnal rhythm of IOP.
The mechanism(s) by which sex hormones may modulate IOP are unclear. IOP is maintained as the result of a balance between the secretion of aqueous humor by the ciliary processes and the outflow of aqueous humor through the trabecular meshwork and uveoscleral pathway. The lack of change in aqueous flow rate during menstrual cycle 11 and gestation 22 suggests that the alterations in IOP related with hormonal changes are mainly a consequence of altered outflow facility, supported by the findings of previously mentioned studies. 7, 8 Nathanson and McKee 23 showed an enrichment of nitric oxide (NO) synthase in human outflow system (trabecular meshwork, Schlemm's canal, and collecting channels) and in the ciliary muscle, especially its anterior longitudinal portion. Moreover, direct topical or intracameral application of NO agonists has been reported to alter outflow facility in experimental studies 24, 25 , probably through relaxation of actin and myosin containing cells in the outflow pathways. 26 Some clinical reports 27 have indicated that the systemic administration of NOmimicking nitrovasodilators can lower IOP. The IOPmodulating effects of sex hormones could in part be mediated through hormone-induced changes in NO synthase activity. It is well established that 17-beta estradiol induces NO synthase in cultured endothelial cells and estrogen-induced vasodilation is mediated through NO generation. 28 However, the actions of androgens on NO synthase activity are not clear and discrepancies have been observed in the actions of testosterone in regulating NO synthase activity in different organs of the body. [29] [30] [31] Many actions of testosterone are mediated by its conversion to estradiol by the enzyme estradiol aromatase followed by binding to the estrogen receptors 32 , but testosterone can also be converted to its potent metabolite, dihydrotestosterone (DHT), by the enzyme 5␣ reductase and act directly on androgen receptors. 33 Thus, testosterone may act like estradiol to increase NO synthase in areas of the body where aromatase is present, whereas it would decrease NO synthase in other areas where 5␣ reductase is present. Considering the fact that androgen receptor protein and 5␣ reductase mRNAs exist in a variety of ocular tissues 34, 35 , it might be speculated that testosterone, by acting through androgen receptors may negatively regulate the NO synthase activity in the outflow pathway and ciliary muscle, and thus may induce an increase in IOP.
In conclusion, menopause is associated with many other changes besides the change in concentrations of the hormones measured in this study, and it is difficult to evaluate an individual hormone effect on a dynamic function like IOP, which is subject to many acute and long-term influences. The results of this study suggests that that higher testosterone levels in menopausal women may tend to increase IOP, although a direct cause and effect relationship remains to be established.
